Rapid Method for Sensitive Screening of Oligosaccharide Epitopes in the Lipooligosaccharide from *Campylobacter jejuni* Strains Isolated from Guillain-Barré Syndrome and Miller Fisher Syndrome Patients⁷†

Monika Dzieciatkowska,¹ Xin Liu,¹ Astrid P. Heikema,² R. Scott Houliston,¹ Alex van Belkum,² Elke K. H. Schweda,³ Michel Gilbert,¹ James C. Richards,¹ and Jianjun Li^{1*}

Institute for Biological Sciences, National Research Council Canada, Ottawa, Ontario, Canada K1A 0R6¹; Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands²; and Clinical Research Centre, Karolinska Institute and University College of South Stockholm, NOVUM, S-141 86 Huddinge, Sweden³

Received 10 April 2008/Returned for modification 30 July 2008/Accepted 19 August 2008

Campylobacter jejuni lipooligosaccharide (LOS) can trigger Guillain-Barré syndrome (GBS) due to its similarity to human gangliosides. Rapid and accurate structural elucidation of the LOS glycan of a strain isolated from a GBS patient could help physicians determine the spectrum of anti-ganglioside antibodies likely to be found and therefore provide valuable assistance in establishing an appropriate course of treatment. The ability of implemented mass spectrometry-based approaches in a clinical setting has been limited by the laborious and time-consuming nature of the protocols, typically 3 to 4 days, used to prepare LOS. In order to improve the analytical throughput, microwave-assisted enzymatic digestion was investigated. In this study, the bacterial cells were suspended in 50 μ l of 20 mM ammonium acetate buffer containing DNase and RNase and treated by direct microwave irradiation for 3 min. Then, proteinase K was added and the samples were again microwaved. The intact LOS samples were analyzed using electrophoresis-assisted open-tubular liquid chromatography-mass spectrometry. The reliability of the rapid, high-throughput technique was demonstrated through analysis of LOS glycans from 73 *C. jejuni* strains. The structure was elucidated using material from a single colony. The total time for sample preparation and MS analysis is less than 60 min.

Guillain-Barré syndrome (GBS) is a postinfection autoimmune-mediated neuropathy that can be triggered by the display of lipooligosaccharide (LOS)-bound ganglioside mimics by the bacterium Campylobacter jejuni (6, 22). Most patients who develop GBS following C. jejuni enteritis have elevated levels of circulating immunoglobulin Gs, which are reactive toward the gangliosides GM1, GD1a, and GQ1b (11, 12). Several studies have linked the onset of GBS with exposure to a surface-bound ganglioside mimic, including animal models where GBS-like symptoms have been triggered following inoculation with C. jejuni LOS bearing a ganglioside mimic (11, 12, 22). Even with prompt medical attention, GBS-associated mortality and disability are highly significant (8), and development of novel therapeutic strategies is an ongoing goal. One attractive treatment option is immunoadsorption therapy, which could be tailored to remove only disease-specific antibodies while returning other serum components to the patient (21). In instances where a C. jejuni strain has been isolated from a GBS patient, rapid determination of its LOS glycan could help establish the adsorption protocol needed for effective treatment.

In recent years, considerable progress has been made toward the elucidation of the molecular determinants of pathogenassociated human diseases. A number of studies have demonstrated that there is a high level of variability in the LOS biosynthesis loci carried by C. jejuni; however, only select strains have the ability to synthesize ganglioside mimics and have been linked to autoimmune-mediated neuropathies (6). One complication that limits our ability to link a specific strain with an antibody response in a patient is that bacteria carrying the same genetic complement can express a large repertoire of glycan structures as a result of phase-variable gene expression (4). Furthermore, GBS patients may also be coinfected with multiple strains, with only one involved in triggering the autoimmune response (5, 7). Mass spectrometry (MS) is one of the few techniques which can provide a comprehensive view of the spectrum of glycans displayed by a given isolate and help to characterize multiple strains present in some fecal samples (14).

We have elucidated the LOS glycan structures in several strains associated with GBS and Miller Fisher syndromes (MFS) by using capillary electrophoresis MS (7, 10, 11). In our initial studies, the LOS was typically O deacylated prior to capillary electrophoresis-MS analysis in order to remove the O-linked fatty acid, which improved solubility and reduced aggregation in aqueous solutions. Nevertheless, *C. jejuni* can still contain up to four N-linked fatty acids, resulting in unwanted association with the capillary tube, which led to the implementation of electrophoresis-assisted open-tubular liquid chromatography–electrospray MS (EA-OTLC-MS) to characterize *C. jejuni* LOS (13). Moreover, because O deacylation causes the unwanted removal of biologically important O-linked glycan modifications and is a time-consuming process, we have recently applied the EA-OTLC-MS technique

^{*} Corresponding author. Mailing address: NRC Institute for Biological Sciences, National Research Council Canada, 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6. Phone: (613) 990-0558. Fax: (613) 952-9092. E-mail: Jianjun.Li@nrc-cnrc.gc.ca.

[†] Supplemental material for this article may be found at http://jcm .asm.org/.

⁷ Published ahead of print on 27 August 2008.



FIG. 1. Illustration of sample preparation procedures. CE-MS, capillary electrophoresis-MS.

for the sensitive analysis of small quantities of fully intact LOS (3). For this method, the sample preparation includes 4 hours of proteinase K digestion and 6 hours of DNase/RNase digestion in combination with overnight lyophilization between the steps, which together take 2 days, a time period which would severely limit the usefulness of this method in a clinical setting, where treatment courses must be established as rapidly as possible.

In an effort to develop a more rapid and sensitive means to analyze *C. jejuni* LOS, we investigated the feasibility of microwave-assisted enzymatic digestions for LOS sample preparation. Microwave irradiation can accelerate enzymatic digestion of proteins, where reactions requiring several hours under conventional conditions can be reduced to only a few minutes with very high yields and reaction selectivity (9, 15, 17, 18, 20, 23, 24). Using this strategy, we have determined that *C. jejuni* LOS can be prepared for MS analysis in as few as 6 min following bacterial harvesting. We tested the general applicability of the technique by analyzing the LOS-bound glycan in 73 different *C. jejuni* strains, including many GBS-associated isolates. This rapid and sensitive MS approach could provide timely information to physicians considering treatment options for GBS patients.

MATERIALS AND METHODS

Bacterial cell culture. *C. jejuni* strains were cultured for 24 to 48 h on Mueller-Hinton agar plates in a microaerobic atmosphere at 37°C. LOS was isolated by washing the colonies from the plates and dispersing them in 1.5-ml tubes, each containing 300 μ l of phosphate (P)-buffered saline (pH 7.4). To this, 700 μ l of 100% ethanol was added, and bacterial cells were incubated at room temperature for 1 h. The cells were pelleted (16,000 × g, 2 min), washed twice with 1 ml of ethanol, washed twice with 1 ml of acetone, and air dried.

Conventional LOS preparation. As illustrated in the left panel of Fig. 1, the sample preparation could take as long as 4 days if O deacylation were required.

In this protocol, proteinase K was typically used as the first digestion enzyme to help break down cells, followed by the application of a DNase/RNase cocktail. The dried cells were dissolved in 200 μ l of deionized water, and a 60- μ l aliquot of a 2-mg/ml solution of proteinase K was added to each vial. The suspended cell solutions were incubated at 37°C for 4 h, and the digestion was stopped by raising the temperature to 75°C for 10 min. The solutions were allowed to cool to room temperature and were subsequently freeze-dried. The cells were resuspended in 200 μ J of 20 mM ammonium acetate (Ac) buffer (pH 7.5) containing DNase (100 μ g/ml) and RNase (200 μ g/ml) and incubated at 37°C for 6 h before being lyophilized. The digested cells were resuspended in 200 μ l of deionized water. Following ultracentrifugation (436,000 × g, 4°C, 1 h), LOS pellets were redissolved in water and lyophilized.

Microwave-assisted LOS preparation. Under microwave irradiation, the enzymatic digestion was carried out for only 3 minutes (right panel of Fig. 1). Since proteinase K can also digest DNase and RNase, we added proteinase K after DNase/RNase digestion without a denaturing step. We found that for microscale sample preparation, there were no significant differences when the order of reagent additions was changed. The bacterial cells were suspended in 50 μ l of 20 mM ammonium Ac buffer (pH 7.5) containing DNase (100 µg/ml) and RNase (200 µg/ml). A container with 100 ml of water was placed beside the sample vials to absorb the excessive microwave energy. The samples were heated by direct microwave irradiation using a domestic 1,200-W microwave oven, with the power level being set at "level 2," for 3 min (Panasonic, Ontario, Canada). Then, proteinase K was added to give a final concentration of 60 µg/ml and heated under the same conditions. The solutions were allowed to cool at room temperature and subsequently dried using a Speed Vac (vacuum centrifuge concentrator; Savant). Overall, with this protocol the sample preparation time was shortened from between 3 and 4 days to less than 1 hour. LOS samples were washed three times with methanol (100 µl) with vigorous stirring, and the insoluble residues were collected by centrifugation and suspended in 30 µl water for EA-OTLC-MS analysis.

EA-OTLC-MS analysis. The detailed experiment procedures of EA-OTLC-MS have been reported previously (13). Briefly, 1.0 μ l of a LOS sample was injected into a capillary column, followed by washing with 1.0 μ l 100% methanol. A small plug (60 nl) of 1.0 M ammonium Ac in deionized water was injected to elute the adsorbed intact LOS from the capillary surface. The separation was performed using 30 mM morpholine in deionized water, pH 9.0. A separation voltage of 20 kV, together with a pressure of 50 kPa, was applied for the EA-OTLC-MS analysis. The electrospray ionization voltage applied on the sprayer was set at -5.2 kV. Data acquisition was performed for an *m*/z range of 600 to 1,800 at a 2-s/spectrum scan rate.

For all the MS experiments, nitrogen was used as both a curtain and a collision gas. In the tandem MS (MS/MS) (enhanced product ion scan) and MS/MS/MS experiments, the scan speed was set to 4,000 Da/s, with Q_0 trapping. In MS/MS and MS/MS/MS experiments, the trap fill time was set as "dynamic" and the resolution of Q_1 was set as "unit." For MS/MS experiments, the excitation coefficient was set to excite only the first isotope for a singly charged precursor, and the excitation time was set at 100 ms.

RESULTS

Analysis of intact LOS samples prepared using conventional protocols. Initially, the intact LOS from C. jejuni MF6 was prepared using a traditional method, and the mass spectrum showed abundant quadruply charged ions with m/z values of 1,096.2 and 1,126.9, together with their corresponding triply charged ions with m/z values of 1,461.6 and 1,502.5 (Fig. 2). In addition, a quadruply charged ion and its triply charged counterpart ion were detected at m/z values of 1,137.5 and 1,516.7, corresponding to the presence of an acetyl group. The MS spectrum can be used to derive the compositions of each glycoform and confirmed by performing MS/MS. The fragment ions with m/zvalues of 290.2 and 581.2 for both precursor ions with m/z values of 1,126.9 and 1,137.5 give evidence for the existence of monosialic acid (N-acetylneuraminic acid [Neu5Ac]) and disialic acid (Neu5Ac-Neu5Ac), respectively (Fig. 3). The fragment ion with an m/z of 332.2, corresponding to O-acetylated Neu5Ac, and the fragment ion with an m/z of 623.3, corresponding to the additional



FIG. 2. EA-OTLC-MS analysis of intact LOS from *C. jejuni* MF6 prepared using a traditional method. A separation voltage of 20 kV, together with a pressure of 50 kPa, was employed. Samples (1.0 μ l) were injected. (A) Total ion chromatogram (*m*/*z* values of 600 to 1,800) and extracted ion chromatogram (*m*/*z* of 1,096.2); (B) extracted mass spectrum at 4.5 min.

attachment of Neu5Ac, were observed only in the tandem mass spectrum of the ion with an m/z of 1,137.5. This observation clearly indicated that the *O*-acetyl group was linked to the Neu5Ac residue. Indeed, the identification of O-acetylated sialic acids is an analytical challenge (16). Mild acid treatment results in Neu5Ac cleavage due to the acid lability of ketosidic linkage, while hydrazinolysis leads to removal of the ester-linked acyl groups. Therefore, direct analysis of intact LOS offers a powerful tool for sialome studies (1, 2, 16, 19).

The lipid A portion of the molecule consisted of a hybrid backbone of β-D-2,3-diamino-2,3-dideoxy-D-glucose (β-D-GlcN3N)- $(1\rightarrow 6)$ - α -D-GlcN3N carrying P or pyrophosphoethanolamine (PPEtn) at positions O-1 and O-4' and substituted by six fatty acid chains. Two major acylation patterns of lipid A were detected as type 1 (four N-linked 3-OH-C_{14:0} and two O-linked C_{16:0} fatty acids) or type 2 (four N-linked 3-OH-C_{14:0} fatty acids, one O-linked C_{14:0} fatty acid, and one O-linked $C_{16:0}$ fatty acid). The MS/MS data also provided the information on lipid A composition, as summarized in Table 1. To locate the glycine residue in the inner core oligosaccharide, MS/MS experiments were performed on core oligosaccharide samples (3). The results revealed that glycine was located on the second heptose residue (Hep_{II}). Structural information on the linkage of glycine residue is under investigation.

Analysis of intact LOS prepared using microwave-assisted digestion. For LOS sample preparation, proteinase K was typically used as the first digestion enzyme to help break down cells, followed by the application of a DNase/RNase cocktail. However, for small colony samples, we found that there were



FIG. 3. MS and MS/MS analysis of intact LOS from *C. jejuni* MF6. A separation voltage of 20 kV, together with a pressure of 50 kPa, was employed. Samples (1.0 μ l) were injected for all experiments. For MS/MS analysis, N₂ was used as a collision gas and -40 V was set as the collision energy level. (A) Extracted MS/MS spectrum of the ion with an *m/z* of 1,126.9 ([M-4H]⁴⁻); (B) extracted MS/MS spectrum of the ion with an *m/z* of 1,137.0 ([M-4H]⁴⁻).

no significant differences based on the order of reagent additions. Since proteinase K can also digest DNase and RNase, we added proteinase K right after DNase/RNase digestion without a denaturing step. To optimize the reaction conditions, microwave-assisted DNase/RNase digestion for five samples was initially carried out for 3 minutes. The five samples were digested with proteinase K for 1, 2, 3, 4, and 5 min. The extracted spectra for the samples with digestion times of 1, 3, and 5 min are presented in Fig. 4; for these samples, the optimal reaction time for proteinase K digestion was 3 minutes. When the reaction time was too long, the sample overheated and LOS degradation occurred, which was evident from the higher peaks associated with the lipid A moiety (e.g., m/zvalues of 987.2, 1,001.2, and 1,022.8) in Fig. 4C. Similarly, the time course of DNase/RNase digestion was investigated with a fixed reaction time of 3 min for proteinase K, and 3 min was also found to be the optimal time period for DNase/RNase digestion (data not shown). In all subsequent experiments, enzymatic digestion was carried out for only 3 minutes. Overall, with this protocol the sample preparation time was shortened from between 3 and 4 days to less than 1 hour (Fig. 1).

Characterization of trace amounts of LOS. The reproducibility of the proposed protocol was evaluated with five replicate samples, each of them containing the cells from five colonies of *C. jejuni* MF6. The results for EA-OTLC-MS analysis are displayed in Fig. 5, and each spectrum demonstrated an excellent signal-to-noise ratio. The observed ions in the replicate samples were essentially identical to each other and to those detected from the whole-plate cell cultures or from dilutions thereof.

The sensitivity of the method was demonstrated through successful and reproducible characterization of single-colony samples, including that with MS and MS/MS. Figure 6 clearly indicates that the detection limit of the technique is at least at the single-colony level. The major glycoforms in all singlecolony samples were the same as those in the five-colony sam-

ŝ
se
^a ly
Ĩ
0
4S
5
4
2
Ľ,
а
1S
4
Ы
÷
ŝ
)a:
61
Ē
Σ
F
.a.
sti
u.
m
je]
r i
\sim
÷
of
OS of
LOS of
t LOS of
tact LOS of
intact LOS of
r intact LOS of
for intact LOS of
ns for intact LOS of
ons for intact LOS of
itions for intact LOS of
ositions for intact LOS of
npositions for intact LOS of
ompositions for intact LOS of
compositions for intact LOS of
ed compositions for intact LOS of
osed compositions for intact LOS of
pposed compositions for intact LOS of
proposed compositions for intact LOS of
1 proposed compositions for intact LOS of
nd proposed compositions for intact LOS of
1 and proposed compositions for intact LOS of
ata and proposed compositions for intact LOS of
data and proposed compositions for intact LOS of
IS data and proposed compositions for intact LOS of
MS data and proposed compositions for intact LOS of
1. MS data and proposed compositions for intact LOS of
2 1. MS data and proposed compositions for intact LOS of
LE 1. MS data and proposed compositions for intact LOS of
BLE 1. MS data and proposed compositions for intact LOS of

		$\begin{array}{c} O^{-}(C_{14:0}), \ 1 \ O^{-}(C_{16:0}) \\ O^{-}(C_{16:0}) \\ O^{-}(C_{16:0}) \\ O^{-}(C_{16:0}) \\ O^{-}(C_{16:0}) \end{array}$	$\begin{array}{c} \widetilde{O}^{-}(\widetilde{C}_{14:0}), \ 1 \ O^{-}(\widetilde{C}_{14:0}), \ 0^{-}(\widetilde{C}_{16:0}), \ 0^{-}(\widetilde{C}_{16:0}), \ 0^{-}(\widetilde{C}_{16:0}), \ 1 \ 0^{-}(\widetilde{C}_{16:0}), \ 1 \ 0^{-}(\widetilde{C}_{16:0}), \ $	$O_{-}(C_{16:0})$ $O_{-}(C_{16:0})$ $O_{-}(C_{14:0})$, 1 $O_{-}(C_{16:0})$	$\begin{array}{c} O^{-}(C_{16:0})\\ O^{-}(C_{16:0})\\ O^{-}(C_{14:0}), 1 \ O^{-}(C_{16:0})\\ O^{-}(C_{16:0})\\ O^{-}(C_{16:0})\\ O^{-}(C_{16:0}) \end{array}$	<i>O</i> -(C _{16:0}) .17; for 3-deoxy-D-manno-
Proposed compositions	Acylation in lipid A	$\begin{array}{c} 3 \ N-(3\text{-OH-C}_{14,0}), \ 1 \ O-(3\text{-OH-C}_{14,0}), \ 1\\ 3 \ N-(3\text{-OH-C}_{14,0}), \ 1 \ O-(3\text{-OH-C}_{14,0}), \ 2\\ 3 \ N-(3\text{-OH-C}_{14,0}), \ 1 \ O-(3\text{-OH-C}_{14,0}), \ 2\\ 3 \ N-(3\text{-OH-C}_{14,0}), \ 1 \ O-(3\text{-OH-C}_{14,0}), \ 2\\ 3 \ N-(3\text{-OH-C}_{14,0}), \ 1 \ O-(3\text{-OH-C}_{14,0}), \ 2\\ \end{array}$	3 N-(5-OH-C140) 1 0-(3-OH-C140) 1 3 N-(5-OH-C140) 1 0-(3-OH-C140) 1 3 N-(3-OH-C140) 1 0-(3-OH-C140) 2 3 N-(3-OH-C140) 1 0-(3-OH-C140) 1	$\begin{array}{c} 3 \ N \cdot (3\text{-OH-C}_{14:0}), \ 1 \ 0 \cdot (3\text{-OH-C}_{14:0}), \ 2 \\ 3 \ N \cdot (3\text{-OH-C}_{14:0}), \ 1 \ 0 \cdot (3\text{-OH-C}_{14:0}), \ 2 \\ 3 \ N \cdot (3\text{-OH-C}_{14:0}), \ 1 \ 0 \cdot (3\text{-OH-C}_{14:0}), \ 1 \\ \end{array}$	3 N -(3-OH-C _{14:0}), 1 O -(3-OH-C _{14:0}), 2 3 N -(3-OH-C _{14:0}), 1 O -(3-OH-C _{14:0}), 2 3 N -(3-OH-C _{14:0}), 1 O -(3-OH-C _{14:0}), 1 3 N -(3-OH-C _{14:0}), 1 O -(3-OH-C _{14:0}), 2 3 N -(3-OH-C _{14:0}), 1 O -(3-OH-C _{14:0}), 2 3 N -(3-OH-C _{14:0}), 1 O -(3-OH-C _{14:0}), 2	3 N-(3-OH-C _{14:0}), 1 O-(3-OH-C _{14:0}), 2 (Hex), 162.14; for HexNAc, 203.19; for Hep, 192
	Phosphorylation in lipid A	PPEtn, P PPEtn, P PPEtn, P PPEtn, PPEtn	PPEtn, P PPEtn, P PPEtn, P	PPEtn, P PPEtn, P PPEtn, PPEtn	PPEtti, P PPEtti, PPEtti PPEtti, PPEtti PPEtti, PPEtti PPEtti, PPEtti	PPEtn, PPEtn ed compositions: for hexose
	Sialylation and O modification in core^{b}	Neu5Ac ₁ Neu5Ac ₁ Giy • Neu5Ac ₁ Neu5Ac ₁	Neu5Ac ₂ Neu5Ac ₂ Glv • Neu5Ac ₂	Ac · Neu5Ac2 Gly · Neu5Ac2 Neu5Ac2	Ac · Gly · Neu5Ac ₂ Neu5Ac ₂ Gly · Neu5Ac ₂ Ac · Neu5Ac ₂ Gly · Neu5Ac ₂	Ac \cdot Gly \cdot Neu5Ac ₂ ues based on the following propos
Molecular mass (Da)	Calculated ^a	4,067.3 4,095.3 4,152.3 4,218.3	4,358.5 4,386.5 4,415.5	4,428.5 4,443.5 4,481.5	4,485.5 4,509.5 4,538.6 4,551.5 4,566.6	4,609.7 of molecular mass val
	Observed	4,067.5 4,096.9 4,153.3 4,219.9	4,359.2 4,387.9 4,417.2	4,431.8 4,445.2 4,482.4	4,489.3 4,511.1 4,538.9 4,554.3 4,568.0	4,611.8 e used for calculation
served ion	[M-3H] ³⁻	1,354.8 $1,364.8$ $1,383.3$ $1,405.6$	1,451.9 1,461.4 1,471.4	1,476.0 1,480.6 1,493.2	1,495.0 1,502.5 1,512.0 1,517.0 1,521.5	1,536.0 raged mass units were
m/z of ob	[M-4H] ⁴⁻	$1,015.9 \\ 1,023.1 \\ 1,037.4 \\ 1.054.0 $	1,088.9 1,096.0 1,103.3	1,107.0 1,110.3 1,119.6	1,121.5 1,126.8 1,133.7 1,137.5 1,141.0	1,152.0 ^a Isotope-ave

^b All the glycoforms contain a conserved structure: Hex₄ · HexNAc₁ · Hep₂ · PEtn₁ · KDO₂.

A) 859.8

84

A) 1095.7 1088.9 1126.6 140.7 1461.3 876.6 1023.0 1364.3 1191.1 1001 B) 1095.8 1110.0 1126.5 1088.9 1141.0 1461.3 1023.0 876.7 1001.3 1364.4 Ы. C) 1095.8 1088.8 1126.6 1140.7 1023.0 876.6 1461.3 1001,3 1364.1 D) 1095.7 1088 10.1 876.6 126.6 1461.2 | 1502.3 1001.3 1022.9 1364.0 E) 1095.7 110.2 1126.6 1088. 876.5 1140.9 1461.3 1022.9 1266.9 1364.4 1001.3 1 800 1600 1000 1200 1400 m/z

its potential for future diagnostic and clinical applications. MS/MS experiments were also carried out for intact LOS from

single bacterial colonies. Figure 7 illustrates the product ion spec-









1095.8

FIG. 5. EA-OTLC-MS analysis of five intact LOS samples (A to E), each from five C. jejuni colonies, using the microwave-assisted digestion protocol. The analysis conditions were the same as those for Fig. 2.



FIG. 6. EA-OTLC-MS analysis of five intact LOS samples (A to E), each from a single *C. jejuni* colony. The analysis conditions were the same as those for Fig. 2.

tra of selected ions with m/z values of 1,126.7 (Fig. 7A), 1,137.0 (Fig. 7B), 1,096.0 (Fig. 7C), and 1,106.5 (Fig. 7D). All spectra contained an ion with an m/z of 290.2, indicating the presence of a sialic acid residue, and a fragment ion with an m/z of 581.3, confirming the presence of disialic acid residues. The observation of fragment ions with m/z values of 332.1 and 623.3 in the tandem mass spectra of ions with m/z values of 1,137.0 and 1,106.5 suggested the presence of Ac-Neu5Ac and Ac-Neu5Ac-Neu5Ac, respectively. An absence of fragment ions with m/z values of 332.1 and 623.3 for the product ion spectra of ions with m/z values of 1,126.7 and 1,096 suggested the absence of O-acetylated Neu5Ac in these glycoforms. The ion with an m/z of 1,577.8 was assigned to the core oligosaccharide fragment as expected $(\text{Hex}_4 \cdot \text{HexNAc}_1 \cdot \text{Hep}_2 \cdot \text{PEtn}_1 \cdot \text{KDO}_1)$. In addition, the fragment ion with an m/z of 1,062.5 (doubly charged ion) corresponded to lipid A, consisting of a disaccharide (GlcN3N or 2-amino-2-deoxy-D-glucose [GlcN]) to which two PPEtn, four N-linked 3-OH-C_{14:0}, and two O-linked C_{16:0} fatty acids were attached. The fragment ion with an m/z of 1,001.4 (doubly charged ion) arose from the loss of phosphoethanolamine (PEtn), and that with an m/z of 1,922.9 (singly charged ion) was formed by the loss of the PPEtn residue from the lipid A moiety.

Analysis of intact LOS from GBS/MFS-associated isolates and enteritis controls. The MS spectra of intact LOS from four GBS-associated isolates, GB13, GB11, MF8, and GB4, are presented in Fig. 8A, B, C, and D, respectively. MS/MS results for each selected precursor are presented in Fig. 8E to H. For strains GB13, GB11, and MF8, detection of a fragment with an



FIG. 7. MS/MS analysis of intact LOS from *C. jejuni* MF6 (single colony). All experimental conditions were the same as those for Fig. 3. (A) Extracted MS/MS spectrum of the ion with an *m/z* of 1,126.7 ($[M-4H]^{4-}$); (B) extracted MS/MS spectrum of the ion with an *m/z* of 1,137.0 ($[M-4H]^{4-}$); (C) extracted MS/MS spectrum of the ion with an *m/z* of 1,096.0 ($[M-4H]^{4-}$); (D) extracted MS/MS spectrum of the ion with an *m/z* of 1,106.5 ($[M-4H]^{4-}$).

m/z of 290.2 suggested that the glycoforms were sialylated. The GM1a mimic was found in both GB13 and GB11, but the GD1a mimic was found only in GB11. The disialylation in strain MF8 was confirmed by the observation of a fragment ion with an m/z of 581.3 (Fig. 8G). It has been reported that MF8 expressed a mixture of mono- and disialylated LOS outer cores, whereas ganglioside mimics could not be detected in the LOS GBS-associated isolate GB4 (7). Detailed glycoform populations and chemical mimicry for each strain are summarized in Table 2, in which the variation in the lengths of the fatty acid chains is indicated as well.

To further evaluate the application of the proposed strategy, a total of 73 clinical isolates were analyzed, and the data are summarized in Table S1 in the supplemental material. LOS outer core structures had already been proposed for the two MFS strains (MF6 and MF8) and 19 of the 21 GBS strains (the two exceptions being GB29 and GB30) by using O-deacylated LOS (7). We analyzed the intact LOSs of these strains by using the microwave preparation method and obtained mass species consistent with the structures proposed previously on the basis of the method using O-deacylated LOS. Moreover, we were able to determine if glycine was present in the LOSs of these strains. Intact LOS samples of the remaining GBS strains (GB29 and GB30) and enteritis controls (matched for age and sex) were also analyzed. We compare the occurrences of various sialic acid species in strains from patients who developed



FIG. 8. EA-OTLC-MS and EA-OTLC-MS/MS of intact LOS. All experimental conditions were the same as those for Fig. 3. (A) Strain GB13; (B) strain GB11; (C) strain MF8; (D) strain GB4; (E) product ion spectrum with an m/z of 1,134.8 ($[M-4H]^{4-}$); (F) product ion spectrum with an m/z of 1,086.1 ($[M-4H]^{4-}$); (G) product ion spectrum with an m/z of 1,035.4 ($[M-4H]^{4-}$); (H) product ion spectrum with an m/z of 1,081.4 ($[M-4H]^{4-}$).

GBS/MFS and an enteritis control. As expected, sialic acid is clearly associated with GBS/MFS (78.3% versus 65.3% for enteritis controls). It is also interesting to note that glycine has a greater extent in GBS/MFS strains (91.3%) than in the enteritis control (69.4%). We do not consider the glycine residue a part of chemical mimicry; however, the presence of glycine on L-glycero-D-manno-heptose (Hep) may influence the conformation of LOS and consequently the epitope presentation. Further studies are under way to establish the genetic base for glycine expression and its biological function.

DISCUSSION

The combination of microwave-assisted digestion and EA-OTLC-MS analysis has allowed us to rapidly characterize *C*.

jejuni LOS in order to accurately determine the glycan composition. Our method is not only rapid but also very sensitive and requires minimal material, as demonstrated by successful analysis using single-colony samples. The application of this technique has also enabled us to detect LOS-bound O-acetylated sialic acid and modification with O-linked glycine. The presence of glycine has previously been detected as a substituent in the second heptose of LOS (3), although the structural information on the linkage of the glycine residue could not be detected for C. jejuni LOS. This MS approach could complement conventional serological techniques used for the detection and identification of GBS-associated C. jejuni strains. Because this technique can identify the complete spectrum of ganglioside-like epitopes expressed by a given strain and also help to characterize strains in the case of infection by multiple strains, an MS approach may provide reliable indication as to

Strain	m/z of observed ion		Den la construction		Ganglioside
	[M-4H] ⁴⁻	[M-3H] ³⁻	Proposed composition	Core structure	mimicry
GB13	1,097.2	1,463.1	Neu5Ac ₁ · Hex ₆ · HexNAc ₁ · Hep ₂ · PEtn ₁ · KDO ₂ · lipid A^b (PPEtn, P)	Gal-GalNAc-Gal-Gal-Hep _{II} -Hep _I	GM1a
	1,104.2	1,472.7	Neu5Ac ₁ ^{\cdot} Hex ₆ · HexNAc ₁ · Hep ₂ · PEtn ₁ · KDO ₂ · lipid A (PPEtn, P)	Neu5Ac Gal Glc Glc	
	1,127.8	1,504.1	Neu5Ac ₁ · Hex ₆ · HexNAc ₁ · Hep ₂ · PEtn ₁ · KDO ₂ · lipid A^b (PPEtn, PPEtn)		
	1,134.8	1,513.4	Neu5Ac ₁ · Hex ₆ · HexNAc ₁ · Hep ₂ · PEtn ₁ · KDO ₂ · lipid A (PPEtn, PPEtn)		
GB11	982.5	1,310.1	Neu5Ac ₁ · Hex ₃ · HexNAc ₁ · Hep ₂ · PEtn ₁ · KDO ₂ · lipid A (PPEtn, P)	Gal-GalNAc-Gal-Hep _{II} -Hep _I	GM1a
	1,013.4	1,351.6	Neu5Ac ₁ · Hex ₃ · HexNAc ₁ · Hep ₂ · PEtn ₁ · KDO ₂ · lipid A (PPEtn, PPEtn)	Neu5Ac Glc	
	1,043.6	1,391.9	Neu5Ac ₂ · Hex ₃ · HexNAc ₁ · Hep ₂ · PEtn ₁ · KDO ₂ · linid A ^b (PPEtn, P)	Gal-GalNAc-Gal-Hep ₁₁ -Hep ₁	GD1a
	1,055.5	1,407.4	Neu $5Ac_2 \cdot Hex_3 \cdot HexNAc_1 \cdot Hep_2 \cdot PEtn_1 \cdot KDO_2 \cdot lipid A (PPEtn, P)$	Neu5Ac Neu5Ac Glc	
	1,074.4	1,432.7	Neu5Ac ₂ · Hex ₃ · HexNAc ₁ · Hep ₂ · PEtn ₁ · KDO ₂ · lipid A ^b (PPEtn, PPEtn)		
	1,086.2	1,448.4	Neu5Ac ₂ · Hex ₃ · HexNAc ₁ · Hep ₂ · PEtn ₁ · KDO ₂ · lipid A (PPEtn, PPEtn)		
	1,127.8	1,504.1	$\begin{array}{l} \text{Neu5Ac}_1 \cdot \text{Hex}_6 \cdot \text{HexNAc}_1 \cdot \text{Hep}_2 \cdot \text{PEtn}_1 \cdot \\ \text{KDO}_2 \cdot \text{lipid } \text{A}^b \text{ (PPEtn, PPEtn} \end{array}$		
	1,134.8	1,513.4	$\begin{array}{l} \text{Neu5Ac}_1 \cdot \text{Hex}_6 \cdot \text{HexNAc}_1 \cdot \text{Hep}_2 \cdot \text{PEtn}_1 \cdot \\ \text{KDO}_2 \cdot \text{lipid A (PPEtn, PPEtn)} \end{array}$		
MF8	931.7	1,242.5	Neu5Ac ₁ · Hex ₃ · Hep ₂ · PEtn ₁ · KDO, · lipid A (PPEtn P)	GalNAc-Gal-Glc-Hep _{II} -Hep _I	GM2
	962.4	1,283.7	Neu $5Ac_1 \cdot Hex_3 \cdot Hep_2 \cdot PEtn_1 \cdot KDQ_2 \cdot linid A (PPEtn PPEtn)$	Neu5Ac Glc	
	982.4	1,310.0	Neu $5Ac_1 \cdot Hex_3 \cdot HexNAc_1 \cdot Hep_2 \cdot PEtn_1 \cdot KDO_2 \cdot lipid A (PPEtn, P)$		
	1,013.3	1,351.4	Neu5Ac ₁ · Hex ₃ · HexNAc ₁ · Hep ₂ · PEtn ₁ · KDO ₂ · lipid A (PPEtn, PPEtn)		
	1,004.6	1,340.0	Neu5Ac ₂ · Hex ₃ · Hep ₂ · PEtn ₁ · KDO ₂ · lipid A (PPEtn, P)	Gal-Glc-Hep _{II} -Hep _I	GD3
	1,035.1	1,380.7	Neu $5Ac_2 \cdot Hex_3 \cdot Hep_2 \cdot PEtn_1 \cdot KDO_2 \cdot lipid A (PPEtn, PPEtn)$	Neu5Ac Glc	
				Neu5Ac	
GB4	1,010.2	1,347.0	Hex ₂ · HexNAc ₃ · QuiNAc ₁ · Hep ₂ · P ₁ · KDO ₂ · lipid A (PPEtn. P)	Unknown	None
	1,040.6	1,388.4	Hex ₂ · HexNAc ₃ · QuiNAc ₁ · Hep ₂ · P ₁ · KDO_2 · lipid A (PPEtn, PPEtn)		
	1,050.5	1,401.1	Hex ₃ · HexNAc ₃ · QuiNAc ₁ · Hep2 · P ₁ · KDO ₂ · lipid A (PPEtn, P)		
	1,081.5	1,442.1	$\begin{array}{c} \text{Hex}_{3} \cdot \tilde{\text{HexNAc}}_{3} \cdot \tilde{\text{QuiNAc}}_{1} \cdot \text{Hep} 2 \cdot P_{1} \cdot \\ \text{KDO}_{2} \cdot \text{lipid A (PPEtn, PPEtn)} \end{array}$		

TABLE 2. MS data and proposed compositions for intact LOS expressed by C. jejuni GB13, GB11, MF8, and GB4^a

" GalNAc, N-acetylgalactosamine; Gal, galactose; Glc, glucose; HexNAc, N-acetylhexosamine; KDO, 3-deoxy-D-manno-oct-2-ulosonic acid; QuiNAc, N-acetylquinovosamine.

^b Lipid A species containing fatty acid chains that are two methylene groups shorter than those in major species.

the range of anti-ganglioside antibodies to be expected in a given patient. MS analysis of additional neuropathy-associated strains from various geographical regions may further expand our insight into the relationship between the structure of the LOS glycan and the clinical symptoms. Immunoassays can provide information about specific epitopes, but MS can provide a more complete picture of the LOS structures being expressed by a strain. It is our hope that accurate molecular fingerprinting of GBS strains provided by MS technology can be transferred from the academic world to a routine diagnostic laboratory. Further, we believe that the techniques outlined in this paper could also be implemented to study the LOSs and lipopolysaccharides from other disease-associated gram-negative bacterial species.

REFERENCES

- Altheide, T. K., T. Hayakawa, T. S. Mikkelsen, S. Diaz, N. Varki, and A. Varki. 2006. System-wide genomic and biochemical comparisons of sialic acid biology among primates and rodents: evidence for two modes of rapid evolution. J. Biol. Chem. 281:25689–25702.
- Corfield, A. P., S. R. Donapaty, S. D. Carrington, S. J. Hicks, R. Schauer, and G. Kohla. 2005. Identification of 9-O-acetyl-N-acetylneuraminic acid in normal canine pre-ocular tear film secreted mucins and its depletion in *Keratoconjunctivitis sicca*. Glycoconj. J. 22:409–416.
- Dzieciatkowska, M., D. Brochu, H. P. Endtz, N. Yuki, R. S. Houliston, J. C. Richards, M. Gilbert, and J. Li. 2007. Mass spectrometric analysis of intact lipooligosaccharide from *Campylobacter jejuni*: the direct evidence for *O*acetylated sialic acid and *O*-glycine. Biochemistry 46:14704–14714.
- Gilbert, M., M. F. Karwaski, S. Bernatchez, N. M. Young, E. Taboada, J. Michniewicz, A. M. Cunningham, and W. W. Wakarchuk. 2002. The genetic bases for the variation in the lipooligosaccharide of the mucosal pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J. Biol. Chem. 277:327–337.
- Godschalk, P. C., M. Gilbert, B. C. Jacobs, T. Kramers, A. P. Tio-Gillen, C. W. Ang, N. Van den Braak, J. Li, H. A. Verbrugh, A. van Belkum, and H. P. Endtz. 2006. Coinfection with two different *Campylobacter jejuni* strains in a patient with the Guillain-Barré syndrome. Microbes Infect. 8:248–253.
- Godschalk, P. C., A. P. Heikema, M. Gilbert, T. Komagamine, C. W. Ang, J. Glerum, D. Brochu, J. Li, N. Yuki, B. C. Jacobs, A. van Belkum, and H. P. Endtz. 2004. The crucial role of *Campylobacter jejuni* genes in anti-ganglioside antibody induction in Guillain-Barré syndrome. J. Clin. Investig. 114: 1659–1665.
- Godschalk, P. C., M. L. Kuijf, J. Li, F. St. Michael, C. W. Ang, B. C. Jacobs, M. F. Karwaski, D. Brochu, A. Moterassed, H. P. Endtz, A. van Belkum, and M. Gilbert. 2007. Structural characterization of *Campylobacter jejuni* lipooligosaccharide outer cores associated with Guillain-Barré and Miller Fisher syndromes. Infect. Immun. 75:1245–1254.
- Hughes, R. A., A. V. Swan, J. C. Raphael, D. Annane, R. van Koningsveld, and P. A. van Doorn. 2007. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 130:2245–2257.
- Juan, H. F., S. C. Chang, H. C. Huang, and S. T. Chen. 2005. A new application of microwave technology to proteomics. Proteomics 5:840–842.
- Koga, M., M. Gilbert, J. Li, S. Koike, M. Takahashi, K. Furukawa, K. Hirata, and N. Yuki. 2005. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 64:1605–1611.
- Koga, M., M. Gilbert, M. Takahashi, J. Li, S. Koike, K. Hirata, and N. Yuki. 2006. Comprehensive analysis of bacterial risk factors for the development of

Guillain-Barré syndrome after *Campylobacter jejuni* enteritis. J. Infect. Dis. **193:**547–555.

- Koga, M., N. Yuki, T. Ariga, and K. Hirata. 1999. Antibodies to GD3, GT3, and O-acetylated species in Guillain-Barré and Fisher's syndromes: their association with cranial nerve dysfunction. J. Neurol. Sci. 164:50–55.
- Li, J., M. Koga, D. Brochu, N. Yuki, K. Chan, and M. Gilbert. 2005. Electrophoresis-assisted open-tubular liquid chromatography/mass spectrometry for the analysis of lipooligosaccharide expressed by *Campylobacter jejuni*. Electrophoresis 26:3360–3368.
- Li, J., and J. C. Richards. 2007. Application of capillary electrophoresis mass spectrometry to the characterization of bacterial lipopolysaccharides. Mass Spectrom. Rev. 26:35–50.
- Lill, J. R., E. S. Ingle, P. S. Liu, V. Pham, and W. N. Sandoval. 2007. Microwave-assisted proteomics. Mass Spectrom. Rev. 26:657–671.
- Schauer, R., H. Schmid, J. Pommerencke, M. Iwersen, and G. Kohla. 2001. Metabolism and role of *O*-acetylated sialic acids. Adv. Exp. Med. Biol. 491:325–342.
- Sun, W., S. Gao, L. Wang, Y. Chen, S. Wu, X. Wang, D. Zheng, and Y. Gao. 2006. Microwave-assisted protein preparation and enzymatic digestion in proteomics. Mol. Cell. Proteomics 5:769–776.
- Swatkoski, S., S. Russell, N. Edwards, and C. Fenselau. 2007. Analysis of a model virus using residue-specific chemical cleavage and MALDI-TOF mass spectrometry. Anal. Chem. 79:654–658.
- Varki, A. 2007. Glycan-based interactions involving vertebrate sialic-acidrecognizing proteins. Nature 446:1023–1029.
- Vesper, H. W., L. Mi, A. Enada, and G. L. Myers. 2005. Assessment of microwave-assisted enzymatic digestion by measuring glycated hemoglobin A1c by mass spectrometry. Rapid Commun. Mass Spectrom. 19:2865–2870.
- Willison, H. J., K. Townson, J. Veitch, J. Boffey, N. Isaacs, S. M. Andersen, P. Zhang, C. C. Ling, and D. R. Bundle. 2004. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. Brain 127:680–691.
- 22. Yuki, N., K. Susuki, M. Koga, Y. Nishimoto, M. Odaka, K. Hirata, K. Taguchi, T. Miyatake, K. Furukawa, T. Kobata, and M. Yamada. 2004. Carbohydrate mimicry between human ganglioside GM1 and *Campylobacter jejuni* lipooligosaccharide causes Guillain-Barré syndrome. Proc. Natl. Acad. Sci. USA 101:11404–11409.
- Zhong, H., S. L. Marcus, and L. Li. 2005. Microwave-assisted acid hydrolysis of proteins combined with liquid chromatography MALDI MS/MS for protein identification. J. Am. Soc. Mass Spectrom. 16:471–481.
- Zhong, H., Y. Zhang, Z. Wen, and L. Li. 2004. Protein sequencing by mass analysis of polypeptide ladders after controlled protein hydrolysis. Nat. Biotechnol. 22:1291–1296.